Key result
Integrating advanced biomarkers, genetics, and machine learning improves adverse CV event prediction over traditional tools.
Why the study?
This article reviews advanced integrative approaches for estimating CVD risk using machine learning and genetic-epigenetic analyses.
Do integrative approaches using machine learning and biomarkers improve cardiovascular disease risk prediction compared to usual risk assessment models?
Do integrative approaches using machine learning and biomarkers improve cardiovascular disease risk prediction compared to usual risk assessment models?
Answers are grounded in this paper and cite their sources.
Integrative approaches combining machine learning, genetics, and biomarkers may improve cardiovascular risk prediction over traditional models.
This article reviews the advanced integrative approaches for estimating cardiovascular disease (CVD) risk by means of machine learning and genetic-epigenetic analyses. A methodical review of 35 studies indicating the prognostic value of several biomarkers-including cardiac troponins, and DNA methylation surrogates-is available in various literatures. These biomarkers were found to improve forecasts of adversative cardiovascular (CV) events and mortality and other CV outcomes. Especially in short-term prediction windows, the integrated model composing of genetics-epigenetics proved better than usual risk assessment models. The results from different literature show how well-advanced biomarker studies and machine learning methods might reduce CV risk assessment, opening the path for tailored preventive programs and improved clinical results. This review article aggregates the outcomes of the various literature for the prediction of CVD, so that the validation of these research models in various populations and merging multi-omics data for more general use will become the future research direction.
No takes yet. Share an insight, caveat, or question.
Rajagopal et al. (2024) conducted a review in Cardiovascular Disease. Machine learning models and advanced biomarkers (genetic/epigenetic) vs. Traditional risk assessment models (e.g., Framingham Risk Score, ASCVD risk estimator) was evaluated on Cardiovascular disease risk prediction accuracy. The integration of advanced biomarkers, genetic-epigenetic data, and machine learning models improved the prediction of adverse cardiovascular events compared to traditional risk assessment tools.
Synapse has enriched 10 related papers. Consider them for comparative context: